Overview

Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Status:
Completed
Trial end date:
2017-05-08
Target enrollment:
Participant gender:
Summary
- To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction - To evaluate the safety and tolerability of oral omecamtiv mecarbil
Phase:
Phase 2
Details
Lead Sponsor:
Amgen
Cytokinetics